Breast Cancer Awareness Month brings a surge of patients back for annual mammograms, and with them an influx of density notices. Since September 2024, FDA rules have required every mammography report to tell patients whether they have dense breasts.1 Many of the questions those notices raise end up with the OB/GYN.
Most of those conversations focus on one problem: dense breast tissue makes a mammogram harder to read. Mammographic sensitivity declines as breast density rises and can fall to 48% in the densest breasts, which means as many as half of cancers in that group may go undetected by mammography alone.2 But a conversation that stops at image quality leaves out the more consequential fact. Dense breast tissue is also an independent risk factor for breast cancer,2 and that changes what OB/GYN follow-up should accomplish.
Dense Breast Tissue Is a Cancer Risk Factor, Not Just a Masking Problem
Nearly half of women 40 and older who get mammograms have dense breasts.3 For each of them, the density finding carries two pieces of information: the screening test performs less reliably, and the patient’s baseline risk is higher.
Estimates of that risk have been refined as imaging has changed. Earlier studies linked extremely dense tissue to anywhere from a one- to six-fold increase in breast cancer risk. A 2022 meta-analysis limited to digital mammography and the current BI-RADS lexicon put it at about 2.1 times the risk of scattered fibroglandular tissue (BI-RADS D vs. B) and roughly 3.9 times the risk of almost entirely fatty tissue (BI-RADS D vs. A).4
The association holds past 65, too. In more than 193,000 women aged 65 and older, heterogeneously or extremely dense tissue remained linked to higher invasive breast cancer risk in both the 65–74 and 75-and-older groups.5
Where Dense Breast Patients Fall Out of the Screening Pathway
When density is framed only as a reason the image was hard to read, a negative mammogram can feel like the end of the story. National data suggests it often is. Among nearly 500,000 U.S. women aged 40 to 74 with dense breasts and negative screening mammograms, only 2.8% of exams were followed by supplemental ultrasound within a year, and 0.3% by MRI.6
Follow-through is unbalanced even when a result clearly calls for action. A systematic review of primary care settings found that between 27.3% and 71.6% of abnormal screening mammograms had not been followed up at six months, with physician-patient miscommunication and logistical barriers among the contributing factors.7
From the patient’s side, the drop-off makes sense. A 45-year-old with a family history schedules her annual mammogram already bracing for bad news. She gets a normal result and a notice about her dense breast tissue, possibly the first time she has heard the term. If the next step means a referral to an outside imaging center, a long MRI with IV contrast, and another wait for results, supplemental screening becomes overwhelming and therefore is avoided.
Reframing the Breast Density Conversation in the OB/GYN Practice
Patients look to their OB/GYN to explain what a density notice means. Discussing breast density, family history, and age together helps each patient understand her personal risk. It also changes how supplemental screening is heard: as appropriate care for a higher-risk patient rather than an extra test to clarify an unclear image.
That framing works best when the next step is close at hand. In the same national cohort of primary care settings, the odds of receiving supplemental ultrasound were more than four times higher at facilities that offered it onsite.6 When the practice that explains the risk can also provide the exam, there is one less handoff for a patient to fall through.
Closing the Dense Breast Screening Gap with SOFIA®
SOFIA® Automated 3D Breast Ultrasound from iVu Imaging brings ABUS technology in-house for OB/GYN practices. Dense breast patients can get accurate cancer screening as a supplemental exam in a setting they already know, without being referred out for imaging and without radiation or contrast injections.8,9
The outcome data are what make that option worth offering. In a prospective study of 1,165 asymptomatic women with dense breasts, adding a prone SOFIA scan to mammography doubled the cancer detection rate: eight cancers, compared with four from mammography alone. Sensitivity rose from 58.8% with full-field digital mammography alone to 93.5% with prone ABUS added.10
The exam is designed to keep patients moving forward. Patients lie prone on a memory-foam bed with no external compression, and a single 30-second sweep captures each breast. Existing clinical staff can run the scan, and each study is sent as a single, high-resolution DICOM-compatible dataset for reading by a local radiologist or breast teleradiologist.8,9 For the practice, that keeps both the exam and the patient in its care.
Breast Cancer Awareness Month puts screening at the top of patients’ minds. For the nearly half with dense breasts, timely screening that matches their actual risk is how cancers get caught at their most treatable stages, and the OB/GYN practice they already trust is well positioned to provide it.
For the full evidence base, download iVu’s white paper, Dense Breast Tissue and the Cancer Screening Gap: A Primer for Women’s Health Providers. To discover how SOFIA brings supplemental dense breast screening in-house for OB/GYN practices, schedule a demo.
Sources
- U.S. Food and Drug Administration. “Important Information: Final Rule to Amend the Mammography Quality Standards Act (MQSA).” Compliance required by September 10, 2024. https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program/important-information-final-rule-amend-mammography-quality-standards-act-mqsa
- Farrokh, A., et al. “SOFIA: A Novel Automated Breast Ultrasound System Used on Patients in the Prone Position: A Pilot Study on Lesion Detection in Comparison to Handheld Grayscale Ultrasound.” Geburtshilfe und Frauenheilkunde 78, no. 5 (2018): 499–505. https://doi.org/10.1055/a-0600-2279
- National Cancer Institute. “Dense Breasts: Answers to Commonly Asked Questions.” Updated December 2, 2025. https://www.cancer.gov/types/breast/screening/dense-breasts
- Bodewes, F. T. H., et al. “Mammographic Breast Density and the Risk of Breast Cancer: A Systematic Review and Meta-analysis.” The Breast 66 (2022): 62–68. https://doi.org/10.1016/j.breast.2022.09.007
- Advani, Shailesh M., et al. “Association of Breast Density with Breast Cancer Risk among Women Aged 65 Years or Older by Age Group and Body Mass Index.” JAMA Network Open 4, no. 8 (2021): e2122810. https://doi.org/10.1001/jamanetworkopen.2021.22810
- Victoria M. Foster, et al. “Supplemental Breast Cancer Screening After Negative Mammography in US Women With Dense Breasts.” Journal of the National Cancer Institute 117, no. 6 (2025): 1271–1275. https://doi.org/10.1093/jnci/djae272
- Reece, Jeanette C., et al. “Delayed or Failure to Follow-up Abnormal Breast Cancer Screening Mammograms in Primary Care: A Systematic Review.” BMC Cancer 21, no. 1 (2021): 373. https://doi.org/10.1186/s12885-021-08100-3
- iVu Imaging. SOFIA 3D Breast Ultrasound Product Brochure.
- iVu Imaging. “OB/GYN & Primary Care.” https://ivuimaging.com/ob-gyn-and-primary-care
- Gatta, G., Cappabianca, S., et al. “Second-Generation 3D Automated Breast Ultrasonography (Prone ABUS) for Dense Breast Cancer Screening Integrated to Mammography: Effectiveness, Performance and Detection Rates.” Journal of Personalized Medicine 11, no. 9 (2021): 875. https://doi.org/10.3390/jpm11090875








.webp)
.webp)

.webp)
.webp)




.webp)











